Rakovina Therapeutics Granted DTC Eligibility to Expand U.S. Investor Access
(TSX-V:RKV),(Boerse Frankfurt – Freiverkehr:7JO0), VANCOUVER, British Columbia, July 15, 2025 (GLOBE NEWSWIRE) — Rakovina Therapeutics Inc. (“Rakovina” or the “Company”) (TSX-V: RKV) (FSE: 7JO0), a biopharmaceutical company advancing next-generation cancer therapies through artificial intelligence (AI)-powered drug discovery, is pleased to announce that its shares are now eligible for electronic clearing and settlement through The Depository […]